1. A pharmaceutical composition comprising an agent capable of activating CD4 + CD25 + regulatory T cells and methotrexate. ! 2. The pharmaceutical composition according to claim 1, where the tool is suitable for parenteral administration. ! 3. The pharmaceutical composition according to claim 2, where the tool is suitable for intramuscular, intravenous or subcutaneous administration. ! 4. The pharmaceutical composition according to claim 1, where methotrexate is suitable for oral, intramuscular, intravenous or subcutaneous administration. ! 5. The pharmaceutical composition according to claim 1, wherein the agent capable of activating CD4 + CD25 + regulatory T cells is an antibody or a fragment or derivative thereof. ! 6. The pharmaceutical composition according to claim 5, where the antibody is a humanized monoclonal antibody. ! 7. The pharmaceutical composition according to claim 6, where the antibody is an anti-CD4 antibody. ! 8. The pharmaceutical composition according to claim 7, where the humanized anti-CD4 antibody contains a sequence comprising the complementarity determining regions (CDRs) of the murine monoclonal antibody B-F5, optionally with variations in the sequence that do not significantly affect the specificity of the antibody and / or its affinity. ! 9. The pharmaceutical composition according to claim 7, wherein the humanized anti-CD4 antibody contains V domains defined by the following polypeptide sequences:! - H chain V domain:! ! - L chain V domain:! ! or V domains containing polypeptide sequences having at least 80% sequence identity with SEQ ID NO: 1 and SEQ ID NO: 2.! 10. The pharmaceutical composition according to claim 1, where the tool is capable of activating CD4 + CD1. Фармацевтическая композиция, содержащая средство, способное к активации CD4+CD25+ регуляторных Т-клеток, и метотрексат. ! 2. Фармацевтическая композиция по п.1, где средство является пригодным для парентерального введения. ! 3. Фармацевтическая композиция по п.2, где с
